Read More

Myriad Genetics Announces Reorganization Of European Operations And Sale Of EndoPredict Business; No Financial Terms Disclosed, Deal Is Subject To Customary Closing Conditions, Expects The Transaction To Close In Q2 Or Q3 Of 2024.

Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the reorganization of its European operations to better align company resources to its domestic opportunities

MYGN

Read More

Chip Designer Synopsys Sells Its Software Integrity Business For ~$2.1B

Synopsys seals a $2.1 billion deal with Clearlake Capital Group, L.P. and Francisco Partners, elevating its focus on core chip design by divesting its Software Integrity Group business to a new standalone entity. Led by existing management, the move aims to revolutionize software development, enhancing innovation while mitigating business risks.

ANSS